Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopp

Trial Details

NCT ID

NCT04267848

Phase

PHASE3

Sponsor

National Cancer Institute (NCI)

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

Biospecimen Collection
Carboplatin
Cisplatin
Computed Tomography
Echocardiography Test
Gemcitabine Hydrochloride

Locations (sample)

Anchorage, Alaska, United States|61.21806,-149.90028
Anchorage, Alaska, United States|61.21806,-149.90028
Anchorage, Alaska, United States|61.21806,-149.90028
Anchorage, Alaska, United States|61.21806,-149.90028
Anchorage, Alaska, United States|61.21806,-149.90028

Key Eligibility Criteria

A female of childbearing potential is a sexually mature female who:
Has not undergone a hysterectomy or bilateral oophorectomy; or
Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months)
Local testing of EGFR with no EGFR exon 19 deletion or EGFR L858 R mutation (applicable to non-squamous patients only)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →